Sales & Marketing News | pharmaphorum

News

AbbVie claims key approval for Vraylar in depression

AbbVie has secured its fourth FDA approval for Vraylar, adding adjunctive therapy of major depressive disorder (MDD) to a list that includes schizophrenia and manic and depressive episodes

News

CSL closes on EU approval for haemophilia B gene therapy

CSL's gene therapy for haemophilia B has been recommended for approval by the EMA's human medicine committee, setting up a decision by the European Commission early next year.

News

Rare disease, repurposing and the role of AI

Changing Faces: pharma supplier, DTx, and non-profit hires f...

A number of pharma-adjacent tech firms and non-profits announced personnel news in the month of November. We’ve rounded up some highlights below.

News

Achievement-so-far-on-objective-on-affordability

Pharma says VPAS clawback jeopardises UK sector

A pharma industry organisation has warned that record levels of revenue clawback from the UK government is threatening "footprint, R&D, and manufacturing investments" in the country.

News

Changing Faces: biopharma hires from November 2022

The month of November saw a number of notable hires and personnel moves in biotech and

News

Lawmakers accuse Pfizer of "pure greed" over COVID jab

Pfizer's decision to raise the price of its COVID-19 vaccine next year has prompted a rebuke from two Democrat senators in the US, who have accused the company of "unseemly profiteering."

AbbVie claims key approval for Vraylar in depression

CSL closes on EU approval for haemophilia B gene therapy

Changing Faces: pharma supplier, DTx, and non-profit hires f...

Pharma says VPAS clawback jeopardises UK sector

Changing Faces: biopharma hires from November 2022

Lawmakers accuse Pfizer of "pure greed" over COVID jab

Regenxbio's Duchenne gene therapy clears phase 3 hurdle

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks